| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Payment of debt issuance costs | 549 | - |
| Net cash provided by financing activities | 459,342 | 242,015 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 138,234 | 49,651 |
| Cash and cash equivalents at beginning of period | 437,391 | - |
| Cash and cash equivalents at end of period | 575,625 | - |
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)